 NEW YORK, May 3, 2021 PRNewswire -- Hoth Therapeutics, Inc. NASDAQ: HOTH a patient-focused clinical-stage biopharmaceutical company, announced it intends to pursue development of its HT-KIT mRNA Frame Shifting Therapeutic for multiple orphan diseases, which are rare diseases that affect less than 200,000 people in the US. HT-KIT targets a shared cell signaling pathway that may have therapeutic potential for multiple rare cancers, including: Aggressive systemic mastocytosis ASM, systemic mastocytosis with associated hematological neoplasm SM-AHN, or mast cell leukemia MCL Acute myeloid leukemia AML Gastrointestinal stromal tumors Drugs intended to treat orphan diseases are eligible to apply for Orphan Drug Designation ODD, which provides multiple benefits to the sponsor during development and after approval. 